 Cidara Therapeutics Inc NASDAQ: CDTX and Mundipharma posted topline data from the ReSTORE Phase 3 trial of rezafungin for candidemia and invasive candidiasis. Rezafungin met the FDA primary endpoint of all-cause mortality at Day 30 and the primary endpoint for the European Medicines Agency EMA submission of global cure at Day 14. 